Physician profile
Ashley Shaw
NPI 1669917522
$2,427.34
in general payments reported to CMS, 2019-2025
21 companies · $603 in 2025
The $603 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $429 · 2023: $446 · 2024: $734 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $374.91 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $219.29 | 2023-2025 | Otezla, Repatha, Repatha |
| Boston Scientific Corporation | $188.03 | 2023-2025 | Solyx Sis System, General - Female Sui, Advantage System |
| Novo Nordisk INC | $166.68 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Scynexis, INC. | $116.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.83 | 2021-2023 | |
| Pfizer INC. | $92.54 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $71.92 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.59 | 2021-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $50.81 | 2024-2025 | Voquezna |
| Abbott Laboratories | $48.13 | 2022-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $41.24 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $35.58 | 2021-2022 | |
| Lilly USA, LLC | $33.99 | 2023-2025 | Jardiance, Emgality |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.31 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $16.99 | 2025 | Auvelity |
| Astellas Pharma US INC | $13.59 | 2025 | Veozah |
| Gilead Sciences, INC. | $13.49 | 2023 | Epclusa |
| Amarin Pharma, INC. | $12.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.